N/A
Completed N=20
Immediate Placement and Stabilization of Dental Implants With Tetranite Stabilization Material in Mandibular and Maxillary Tooth Extraction Sites That Fail to Provide Adequate Primary Stability
Adhesive Dental
Source: ClinicalTrials.gov NCT04121364 ↗
Enrolled (actual)
20
Serious AEs
65.0%
Results posted
Feb 2024
Primary outcomePrimary: Implant Success (Modified Buser Criteria) — 6 participants
Summary
This study is to determine if a new bone adhesive is useful in stabilizing dental tooth implants. Data collected from the study will examine the strength, performance, and the safety of the material.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Implant Success (Modified Buser Criteria) |
6 | — |
| SECONDARY Adverse Events (Serious, Device Related) |
— | — |
Eligibility Criteria
Inclusion Criteria
- Signed Informed Consent;
- 21+ Age;
- Require tooth extraction and replacement with dental implant;
- Have opposing dentition;
- Committed to Study and Follow-up period;
- ASA I or II;
- Planned "implant site" must have 1 adjacent tooth;
- Sufficient bone Height for safe dental implant placement;
- At least 2 mm of apical bone for seating of implant.
Exclusion Criteria
- Any significant disease that would preclude a dental implant
- Any oral surgery contraindications
- Subjects with mucosal Disease
- Subjects with bone diseases or conditions (e.g. Paget's disease, fibrous dysplasia, history of osteomyelitis, etc.) in the region of the potential study implant site;
- Subjects with a history of local radiation therapy in the head/neck area or osteonecrosis of the jaws;
- Subjects with any acute and untreated endodontic lesions or periodontal disease;
- Subjects receiving, or having a recent or long-term history of receiving, oral or parenteral anti-osteoclastic agents [e.g., bisphosphonates, Xgeva® and Prolia® (denosumab); Forteo® (teriparatide), strontium ranelate, etc.], or anti-angiogenesis factors;
- Subjects who have major active substance abuse problems (e.g., alcoholism, opiate addiction, methamphetamine abuse, etc.);
- Subjects who are pregnant or intending to become pregnant during the duration of the study;
- Subjects who are heavy smokers (defined as >10 cigarettes per day or >1 cigar per day or equivalent of electronic cigarette vaping) or chew tobacco;
- Subjects with inadequate oral hygiene or who are unmotivated for adequate home care;
- Subjects who have physical or mental handicaps that would interfere with the ability to perform adequate oral hygiene;
- Subjects who have undergone administration of any investigational device within 30 days of enrollment in the study;
- Subjects who are allergic or otherwise sensitive to any materials likely encountered during the course of the study (e.g. titanium, suture materials, local anesthetics);
- Subjects with conditions or circumstances, which, in the opinion of the Investigator, would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance or unreliability
- Any site into which the implant is not or cannot be placed during the same visit as the extraction;
- Any implant site where there is a dehiscence or fenestration of buccal or lingual plates of bone greater than 5mm in any direction.
Data sourced from ClinicalTrials.gov (NCT04121364). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.